The metabolism and clinical safety of the pivalic acid-containing antibiotic S-1108, an orally active pro-drug cephalosporin, were investigated to assess the clinical effects, with special emphasis on the influence of carnitine consumption in 15 patients with various infectious diseases receiving S-1108 three times a day at a 300-or 600-mg total daily dose for 3 to 7 days. The free carnitine concentrations in plasma were greatly reduced to approximately 65% of pretreatment levels, and the plasma pivaloylcarnitine (the main metabolite of pivaloyloxymethyl ester) concentrations were increased during the 200-mg (three times a day) regimens but returned to the pretreatment levels within 3 to 5 days after the cessation of treatment. In three elderly patients with declining renal function (creatinine clearance rate, 31 to 50 mVmin), the acylcarnitine/free carnitine ratio increased from 0.1 to 0.4 up to 0.7 to 1.5 at day 5 during the 7-day treatment, showed a tendency to decrease, and then returned to the pretreatment ratio 4 days after discontinuation of the drug. The degree of free carnitine reduction and increase of the acylcarnitine/free carnitine ratio depended mostly on the dose and the duration of S-1108 treatment. The increased acylcarnitine/free carnitine ratio in elderly patients was due to reduction of the free carnitine concentration in plasma and mainly to the retardation of nontoxic pivaloylcarnitine excretion. This study indicated that there was a decrease in free carnitine levels in plasma, but there were no clinical symptoms or adverse effects associated with carnitine reduction in patients during the 7-day multiple administration of S-1108.
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S-1108 is a pro-drug type oral cephem antibiotic which has a pivaloyloxymethyl (POM) ester group and which is easily deesterified in the intestine to produce its active component, S-1006, as well as pivalic acid and formaldehyde, as shown in Fig. 1 . The metabolic and pharmacokinetic profiles of S-1108 have been intensively studied, including clinical evaluations with healthy volunteers (6, 8) . Other publications have also shown that the pivalic acid formed by in vivo hydrolysis of the POM ester, pivampicillin, and pivmecillinam was excreted as a conjugate with carnitine (pivaloylcarnitine) and that administration of these drugs consequently gave rise to reduced serum carnitine levels but without clinical symptoms (2, 3, 4) . Carnitine (L-carnitine) is an essential cofactor in fatty acid oxidation and a modulator of the acyl coenzyme A/coenzyme ASH ratio (6) ; therefore, about 100 mmol is present in the adult human (male, 70 kg of body weight) (1) . Almost all carnitine stores (-98%) are in skeletal and cardiac muscle. Camitine is clinically important from a toxicological viewpoint to investigate carnitine utilization of substances containing pivalic acid, since abnormal consumption of carnitine might induce a metabolic dysfunction (2) .
The clinical safety and pharmacokinetics of S-1108 were also studied in a multiple-administration study with day for 1 to 3 days before treatment (control samples) and before the morning dose every day during S-1108 administration and was continued for several days after for a maximum of 2 weeks administration. All blood samples were collected into heparinized tubes and immediately centrifuged under cooling. The plasma samples were stored at -20°C until analysis. Twenty-four-hour urine samples were collected 2 to 3 days before, during, and 3 and 14 days after treatment throughout the study. The volume of the urine sample was measured accurately, and the aliquots from each well-mixed block sample were stored at -20°C until the assay.
Assay methods. Free and total carnitine (free carnitine plus various acylcarnitines) concentrations in plasma and urine samples were determined by enzyme radioassay (8) . The detection limits of carnitine in plasma and urine samples were 6 and 25 nmol/ml, respectively, with a coefficient of variation of 5% for both. The pivaloylcarnitine concentrations in plasma and urine samples were determined by high-performance liquid chromatography (HPLC). The detection limits were 0.02 ,ug/ml for plasma and 1 ,ug/ml for urine, and the coefficients of variation at the assay ranges were less than 4% for both. The pivalic acid concentration in urine was determined by gas chromatography by a method described previously (6, 8) . The detection limits were 0.5 ,ug/ml, and the coefficients of variation at the assay range were less than 3%.
Statistical analysis. The differences in free carnitine levels in plasma before and during treatment were evaluated by using a paired t test at P = 0.05 or 0.01.
Clinical observations and laboratory tests. Clinical observations (subjective and objective symptoms) were made just before each dosing. Laboratory tests (hematology, blood chemistry, and urinalysis) were carried out after each dosing Carnitine status in plasma. The mean concentrations of free carnitine, acylcarnitine, and pivaloylcarnitine (a main metabolite of POM ester) in plasma during the treatment with S-1108 at 100 mg TID for 7 days and at 200 mg TID for 7 days are shown in Fig. 2 . The plasma carnitine concentrations decreased and the plasma pivaloylcarnitine concentrations increased during the multiple-administration regimens. The 200-mg regimen reduced the plasma camitine concentration significantly, as shown in Fig. 2 , and the carnitine concentration with the 200 mg TID 7-day regimen declined to values as low as 20 nmol/ml until the fifth day of treatment, and this concentration was maintained during the treatment period thereafter. After the end of the treatment, the carnitine concentration returned to normal (40 to 50 nmol/ml) within 4 to 5 days.
Carnitine status in urine. The mean daily urinary excretion of free carnitine, acylcarnitine, and pivaloylcamitine for the 100-mg TID and 200-mg TID 7-day regimens are shown in Fig. 3 . During the multiple administration of S-1108, the daily urinary excretion of pivaloylcarnitine increased in a dose-dependent manner to about 500 to 600 ,umol with the 100-mg TID regimen and 900 to 1,000 ,umol with the 200-mg TID regimen (the theoretical amount of pivaloylcarnitine calculated from the 600-mg daily dose was 1,324 ,umol) and decreased rapidly after discontinuation of treatment, although small amounts were detected up to 10 days after discontinuation of treatment. This demonstrates that the daily excretion profile of acylcarnitine (determined by enzyme radioassay) was almost similar to that of pivaloylcarnitine (determined by HPLC) in each time period. The results clearly indicate that most of the excreted acylcarnitine is recovered as pivaloylcarnitine, and the major metabolic pathway of pivalic acid is conjugation with carnitine in the human body.
Pivalic acid in urine. Pivalic acid in urine samples was measured by a gas chromatography method. In nearly all samples, pivalic acid was not detected (detection limit: 0.5 ,ug/ml), and, in the few samples in which the acid was detected, it amounted to less than 1% of the S-1108 administered. DISCUSSION S-1108 is a pro-drug type cephem antibiotic having a POM ester group at the C-4 carboxylic acid. In our previous studies (8) , pivalic acid liberated from the POM ester was conjugated with carnitine in the human body and almost quantitatively excreted in urine as pivaloylcarnitine (Fig. 1) . Also, in the 200-mg TID 8-day regimen conducted with healthy volunteers, there were no clinical symptoms or adverse effects indicating carnitine deficiency (6) . The biological importance and role of carnitine are reported as an essential cofactor in fatty acid oxidation. Therefore, we conducted this multiple administration of S-1108 in patients, paying special attention to the clinical importance of the carnitine status.
Multiple administration of S-1108 resulted in an immediate decrease in the camitine concentration in plasma and an increase in the excretion of pivaloylcarnitine conjugate in urine. The carnitine concentration with the 200-mg TID regimen decreased rapidly to between 50 and 65% of the pretreatment value over 3 days and thereafter decrease gradually to the steady-state level (20 to 30 nmol/ml). The carnitine concentration returned to normal (40 to 50 nmol/ ml) at 3 to 5 days after the cessation of treatment. Consumption of free carnitine in plasma with the 100-mg and 200-mg TID 7-day regimens was judged by comparing the decrease in the area under the curve of the free carnitine concentration-time curve for 7 days of treatment with that of the mean pretreatment level. The decrease in the areas under the curve for the 100-mg and 200-mg TID regimens were 62 and 189 nmol-day/ml, respectively, indicating that the plasma carnitine concentration decreased in a dose-dependent manner. A 200-mg TID 3-day regimen was conducted with one male (62 years old) and two female patients (69 and 73 years old). Their free carnitine levels in plasma at day 3 of drug administration were also reduced to approximately 50, 45, and 49% of pretreatment levels in the one male and two female patients, respectively, but returned to the pretreatment levels within 2 to 5 days after cessation of treatment. There was almost the same reduction in free carnitine levels in plasma in male and female patients with the 200-mg TID regimen. The changes in the carnitine concentration during and after treatment were almost the same in patients as in healthy volunteers for the 7-day regimen reported (6) . The fact that 35% of the carnitine concentrations in plasma could be maintained throughout multiple administration of the drug suggests that there is enough carnitine stored in the human body to overcome the increase in pivalic acid, even at drug doses as high as 200-mg TID, in a manner similar to that found in healthy volunteers, as reported previously (6) . Although some reports (2, 3) have indicated that there was a potential risk associated with use of these pro-drugs that liberate pivalic acid, there was no clinical evidence of adverse effects associated with carnitine deficiency, similar (5) (5) (5) (5) (5) (5) (5) (5) (4) (4) (5) (5) (5) +1 +2 +3 +4 +5 +6 +7 +8 +9 1+101+11+12+13+14 Day (3) (3) (6) (4) (7) (4) (7) (4) (7) (4) (7) (7) (6) (7) (3) (4) to that found in patients treated with pivampicillin and pivmecillinam. In our study with 15 patients, there were also no clinical symptoms derived from carnitine deficiency, such as tiredness, muscle pain on fasting, or increased aldolase or creatinine kinase levels, although a larger number of patients should be tested to confirm these findings. Figure 4 shows the ratio of plasma acylcarnitine to free carnitine concentrations (acyl/free carnitine), a parameter of secondary carnitine deficiency (5) , and the free carnitine concentrations in plasma for the 200-mg TID 7-day regimen before, during, and after treatment. The changes in the acyl/free carnitine ratio correlated inversely with that in the free carnitine concentration. The acyl/free carnitine ratio in patients (60, 76, and 79 years old) with declining renal function (creatinine clearance rate, 31 to 51 ml/min) increased to 0.7 to 1.5 at day 5 during the 7-day treatment; those values are much higher than those observed in patients with normal renal function (up to 0.5 to 0.6), showed a tendency to decrease, and then returned to the pretreatment ratio (0.1 to 0.4) at day 4 after treatment. The free carnitine concentration in plasma for the three patients was almost the [Before Treatment] [Trral same (about 20 nmol/ml) as that for the other four patients with this regimen; therefore, the elevation of the acyl/free carnitine ratio was largely due to the higher acylcarnitine concentration in plasma. Figure 5 shows the linear regression lines between the acyl/free carnitine ratio and free carnitine concentration before during and after S-1108 treatment with the 200-mg TID 7-day regimen. In this figure, the data were plotted separately for the patients with normal renal function and reduced renal function (creatinine clearance rate, <50 ml/min). The higher slope of linear regression might indicate carnitine deficiency (high acyl/free carnitine ratio and low free camitine level) in patients. For the patient with normal renal function, the slope was almost the same as that before treatment. For the patient with reduced renal function, on the other hand, the slope was 3.5 times higher than that of the patients with normal renal function, suggesting that the patients with reduced renal function are likely to have carnitine deficiency. However, the increased acyl/free carnitine ratio shown in this study was due to the reduction of the free carnitine concentration in plasma described above and, furthermore, was due to retardation of nontoxic pivaltment] In conclusion, this study indicated that treatment with S-1108 containing pivalic acid led to a reduction in free carnitine in plasma; however, there were no clinical symptoms or adverse effects associated with carnitine reduction in patients with infectious diseases at daily drug doses of 300 to 600 mg during 7 days of administration. The degree of carnitine reduction might depend on the drug dose and the duration of the treatment. Therefore, S-1108 is safe and well tolerated when administered at the recommended dosage.
